Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Phase 2
Recruiting
- Conditions
- Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Yunnan Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06239870
- Locations
- 🇨🇳
Envafolimab, Kunming, Yunnan, China
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Efficacy and Safety
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Hairong Liu
- Target Recruit Count
- 40
- Registration Number
- NCT06218004
A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Northern Jiangsu People's Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT06108726
- Locations
- 🇨🇳
Northern Jiangsu People's Hospital, Suzhou, Jiangsu, China
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Phase 1
Active, not recruiting
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: KGX101- Cohort 3Drug: KGX101- Cohort -1Drug: KGX101- Cohort 2Drug: KGX101- Cohort 5Drug: KGX101- Cohort 4Drug: KGX101- Cohort 1
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Kangabio AUSTRALIA LTD PTY
- Target Recruit Count
- 54
- Registration Number
- NCT06074497
- Locations
- 🇦🇺
Pindara Private Hospital, Benowa, Queensland, Australia
🇦🇺Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2023-10-11
- Target Recruit Count
- 33
- Registration Number
- NCT06060704
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Phase 2
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06059261
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Mucosal Melanoma
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT06041724
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin
Phase 2
- Conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06030934
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Neoadjuvant TherapyImmunotherapyColon Cancer
- Interventions
- Drug: CAPEOX
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 55
- Registration Number
- NCT06014372
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06010667
- Locations
- 🇨🇳
Hebei, Shijiazhuang, Hebei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath